PCSK9 Forum is made possible thanks to support from AstraZeneca, Lib Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Spire

SPIRE trials: Bococizumab was insufficiently humanized for long-term use

SPIRE trials: Bococizumab was insufficiently humanized for long-term use

The development of bococizumab, the third of the PCSK9 monoclonal antibodies, was discontinued by Pfizer in early November (1). Insights from a late breaker trial presentation provide some answers why this might be the case. SPIRE programme: lipid lowering trials The SPIRE program included 6…

read more »
Posted on 18 March 2017 | Posted in News, Bococizumab, 66th Annual Scientific Sessions of the American College of Cardiology 2017
SPIRE-2: Cardiovascular benefit in very high risk patients

SPIRE-2: Cardiovascular benefit in very high risk patients

Evidence from the two cardiovascular outcomes studies with bococizumab, notably SPIRE-2, added to the buzz around FOURIER. According to PCSK9 Forum Editor Professor Philip Barter (University of New South Wales, Sydney, Australia): ‘Despite follow-up being short due to termination of the development of bococizumab, SPIRE-2…

read more »
Posted on 18 March 2017 | Posted by Philip Barter | Posted in News, 66th Annual Scientific Sessions of the American College of Cardiology 2017
PlayProf Raul Santos: SPIRE trials with bococizumab

Prof Raul Santos: SPIRE trials with bococizumab

The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.

read more »
Posted on 17 March 2017 | Posted by Raul Santos | Posted in Videos, 66th Annual Scientific Sessions of the American College of Cardiology 2017

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved